Related Experiment Video

Updated: Nov 17, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K

[Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]

Yves Fougère1, Marie Rohr2, Pauline Vetter3

  • 1Unité d'infectiologie pédiatrique et vaccinologie, Département femme-mère-enfant, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|February 18, 2021
PubMed

Insights

While most children experience mild COVID-19, severe cases warrant attention. Research is ongoing for effective pediatric treatments, with steroids showing promise for severe illness.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Virology

Background:

  • SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) affects all age groups.
  • Pediatric COVID-19 cases typically present with less severe symptoms compared to adults.
  • Rare severe COVID-19 cases in children necessitate focused research and attention.

Purpose of the Study:

  • To review the current landscape of COVID-19 treatments.
  • To highlight the specific need for pediatric data in treatment studies.
  • To identify gaps in knowledge regarding pediatric COVID-19 therapeutics.

Main Methods:

  • Review of existing scientific literature on SARS-CoV-2 treatments.
  • Analysis of clinical trial data focusing on antiviral and immunomodulatory agents.
  • Synthesis of findings from adult studies and identification of pediatric data gaps.

Main Results:

  • No specific antiviral molecule has demonstrated proven efficacy for COVID-19 to date.
  • Studies on monoclonal antibodies and convalescent plasma for COVID-19 are pending.
  • Steroids have shown benefit in severely ill adult patients; other immunomodulators are under investigation.

Conclusions:

  • Current COVID-19 treatment research predominantly focuses on adult populations.
  • There is a critical need for robust clinical data and treatment studies specifically in pediatric populations.
  • Further investigation into pediatric-specific responses to existing and novel therapies is essential.

More Related Videos

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic09:03

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic

Published on: November 7, 2020

5.2K
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

886

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
102
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
573
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
89
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
100
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
120
Tonsillitis II: Management01:26

Tonsillitis II: Management

This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
259